🔬 Help Advance CAR T-Cell Research for Oncogene-Driven Lung Cancer On October 18, over 200 patients, care partners, and advocates from the ALK-positive, EGFR, HER2, and broader oncogene-driven lung cancer communities joined ALKtALK, in collaboration with EGFR Resisters…

to hear Dr. Kyle Concannon from the University of Colorado Anschutz Medical Campus. He shared his work on active-conformation EGFR-specific (ACES) CAR T cells, a new approach designed to find and attack the cancer cells that survive targeted therapy. For many of us, that is the question that matters most. ALK inhibitors have given us more time than ever before, but resistance remains the reality we all live with. CAR T-cell therapy has already changed what is possible for some blood cancers. Dr. Concannon’s research asks whether engineered immune cells could do the same for oncogene-driven lung cancer, and possibly work alongside the targeted therapies we already rely on. The ACES program includes ALK-positive and EGFR arms, and our communities have the chance to help move it forward. Research at this stage is needed to build the evidence for a first clinical trial. This research is still early. That is exactly why patient-funded support matters: early-stage science is often the hardest to fund, and our communities can help shape what gets studied and how quickly. Together, we can help create more possibilities for people living with oncogene-driven lung cancer. Watch the ALKtALK replay to learn more about Dr. Concannon's research and how our communities can help move this work forward. ▶️ https://youtu.be/30skcFExCPA?si=KV6bYX9ZGY0gB63X Stay informed. Become empowered.